Frederick Beddingfield, Kira CEO
Kira and its complement-target inhibitors plot run to the clinic with new investor cash just months after uncloaking
A couple months after emerging from stealth, Kira Pharmaceuticals has reeled in its largest venture round yet to fund a dash to the clinic …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
